Objective-To study the distribution of group V secretory phospholipase A 2 (sPLA 2 ) in human and mouse lesions and compare its expression by human vascular cells, its activity toward lipoproteins, and the interaction with arterial proteoglycans (proteoglycans) with those of sPLA 2 -IIA. In addition, we also investigated the effect of a Western diet and lipopolysaccharide challenge on the aortic expression of these enzymes in mouse models. Methods and Results-Immunohistochemistry showed sPLA 2 -V in human and mouse lesions to be associated with smooth muscle cells and also surrounding foam cells in lipid core areas. mRNA of the enzyme was expressed in human lesions and human vascular cells, supporting the immunohistochemistry data. sPLA 2 -V but not sPLA 2 -IIA was active on lipoproteins in human serum. The association with proteoglycans enhanced 2-to 3-fold sPLA 2 -V activity toward low-density lipoproteins but not that of the group IIA enzyme. Experiments in mouse models showed that treatment with a Western diet induced expression of sPLA 2 -V but not that of sPLA 2 -IIA in aorta. On the other hand, lipopolysaccharide-induced acute inflammation augmented the expression of sPLA 2 -IIA but not that of sPLA 2 -V. 
D uring atherosclerosis development, there is a progressive decrease of the lesion phospholipid content and enrichment in cholesterol. 1 Furthermore, apolipoprotein B (apoB) lipoproteins isolated from human and rabbit lesions contain less phosphatidylcholine (PC) and more sphingomyelin than circulating lipoproteins. 2, 3 Therefore, lipoproteins trapped in the intima appear to be hydrolyzed by secretory phospholipases. 4 These enzymes may contribute to atherosclerosis by hydrolysis of low-density lipoprotein (LDL) phospholipids that induce fusion and increase binding of cholesterol-rich particles to intima proteoglycans, triggering further modifications. [5] [6] [7] [8] In addition, phospholipase(s) A 2 contribute to local release of lyso-phospholipids and nonesterified fatty acids, which have proinflammatory properties in arterial cells. 9 -12 
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Secretory phospholipase A 2 (sPLA 2 ) group IIA is present in human atherosclerotic lesions, and experimental and clinical evidence suggest its involvement in atherosclerosis and cardiovascular disease. [13] [14] [15] [16] [17] sPLA 2 -IIA and the more recently cloned sPLA 2 -V are members of a family of enzymes that hydrolyze the fatty acids at the sn-2 position of glycerophospholipids. Both enzymes have low molecular weight (14 kDa) , are histidine and calcium dependent, rich in disulfide bonds, are basic, and share structure similarities. 18 Several of these properties stabilize and enhance their activity in the extracellular milieu. The genes of sPLA 2 -IIA and sPLA 2 -V enzymes are located at close positions in homologous regions in mouse chromosome 4 and human chromosome 1 and share the same promoter. 19 This region was identified as an atherosclerosis susceptibility locus in the LDL receptordeficient mouse and is considered a human candidate locus. 20 The C57BL/6 mouse strain is a natural knockout of sPLA 2 -II because a frame shift mutation in exon 3 blocks gene translation. 21 Therefore, either sPLA 2 -IIA does not contribute to atherogenesis in this mouse strain, or other(s) sPLA 2 compensates its absence. On the other hand, the human sPLA 2 -IIA transgenic mouse is more susceptible to atherosclerosis than its littermates that only express the group V. 13, 16 This suggests that the expression of both enzymes may contribute to lesion formation. The group V sPLA 2 is also present in human atherosclerotic lesions, but the cell source and regulation of sPLA 2 -V activity in lesions are unknown. 22 Here, we report on the immunohistochemical localization and cell association of sPLA 2 -V in human and mouse lesions. We compared the mRNA expression in human lesions and vascular cells, the activities on lipoproteins, and modulation by extracellular arterial proteoglycans of sPLA 2 -V and sPLA 2 -IIA. In addition, we investigated in mouse models the effect of a Western diet and acute inflammation on the aortic expression of the enzymes.
Materials and Methods
The Materials and Methods section is available online at http://atvb.ahajournals.org.
Results

Immunohistochemical Staining of sPLA 2 -V in Human Lesions
The specificity of all used antibodies was evaluated by Western blotting, and no cross-reactivity of the antibodies against the 2 enzymes was detected (supplemental Figure I , available online at http://atvb.ahajournals.org). The antibodies against sPLA 2 -IIA that we used in our previous studies 5, 23 were also specific and did not cross-react with sPLA 2 -V. Figure 1 shows serial sections of 3 human atherosclerotic lesions. Figure 1A , 1D, 1G, 1J, 1N, and 1O are from an advanced lesion characterized by a thick intima and a well-formed necrotic lipid core. The second column ( Figure  1B , 1E, 1H, 1K, 1L, 1P, and 1Q) shows sections from an intermediate type of aortic lesion characterized by a thick neointima with foam cells and a defined media, still with no tissue damage. The third column ( Figure 1C, 1F, 1I , 1M, and 1R) shows sections from an advanced type of lesion in coronary artery characterized by a confluent mass of extracellular lipids (lipid core) and a structural altered intima. Actin-positive smooth muscle cells (SMCs) were present in the media and intima in all 3 lesion types ( Figure 1A through 1C, arrows). CD68-positive macrophages were present only in the intima and lipid core of the lesions ( Figure 1D Figure 2 shows serial sections from lesions of 2 individual apolipoprotein E and low-density lipoprotein receptor (apoEϫLDLr) double deficient mice ( Figure 2A through 2E and 2H). There were similarities in the immunohistochemical distribution of sPLA 2 -V and that described above for human lesions, with the exception that the enzyme was not detected in mice endothelium (supplemental Figure III) . This could have been caused by endothelium disruption during perfusion. Immunostaining showed shared areas positive for sPLA 2 -V ( Figure 2A and 2E, arrows) and apoB ( Figure 2B and 2F, arrows) using serial consecutive sections. More extensive colocalization was observed between macrophagerich areas ( Figure 2D The levels of sPLA 2 -IIA mRNA were 1000-fold higher than those of sPLA 2 -V in all 3 different sources of SMCs in culture, but the relative order of expression for different cells was similar (Figure 3) . However, no expression of sPLA 2 -IIA was detected in M⌽, M⌽-loaded with lipids by incubation with acetylated LDL, or in arterial endothelial cells, whereas low levels of sPLA 2 -V mRNA were consistently present in these cells. The expression levels for both enzymes in human fibrotic lesion samples and CD14-positive lesion macrophages were different between samples (donors) but always Ն2-fold higher for sPLA 2 -IIA than sPLA 2 -V (supplemental Figure IV) . Expression levels of the housekeeping gene, 36B4, were similar between the different tissue samples and cultured cells (data not shown).
Immunohistochemical Staining of sPLA 2 -V in Mouse Lesions
Activity of Recombinant sPLA 2 -IIA and sPLA 2 -V on Human Serum and Lipoproteins
Both enzymes were equally active hydrolyzing phosphoethanolamine micelles and showed substrate specificity (supple- . Kinetic analysis showed that the VLDL surface phospholipids was the preferential substrate for sPLA 2 -V with a K m ϭ546 mol/L (substrate concentration that gives one-half the maximum velocity), followed by HDL and LDL with a K m of 1320 mol/L and 3000 mol/L, respectively (Figure 4 ). High-performance liquid chromatography analysis of all lipid classes in VLDL, LDL, and HDL incubated 24 hours with recombinant sPLA 2 -V showed a decrease in PC content of all lipoproteins. The phosphatidylethanolamine content was also decreased significantly in VLDL and LDL but not in HDL. This was accompanied by a significant increase in the corresponding lyso-phospholipids (Table) . No changes were observed in other lipid classes (data not shown), thus indicating that sPLA 2 -V is specific for lipoprotein phospholipids. Complex formation of LDL with proteoglycans can contribute to retention of the LDL in the intima. 24 We found that treatment with sPLA 2 -V increased the LDLproteoglycans complex formation 20-to 25-fold. Using similar conditions, treatment of LDL with sPLA 2 -II resulted in no increase of the LDL-proteoglycans complex (supplemental Figure VIII) .
Interaction of sPLA 2 With SMC Proteoglycans
sPLA 2 -IIA resides in the extracellular intima associated to proteoglycans, a situation that facilitates its action on lipoproteins also bound to the sulfated polysaccharides. The immunohistochemical results discussed above suggest that this could also occur with the group V enzyme (Figure 1 ). Gel mobility shift assay with metabolically labeled chondroitin-6-sulfate proteoglycans synthesized by human aortic SMCs showed that SPLA 2 -IIA was bound to proteoglycans with an apparent affinity constant (k d ) of 19 nmol/L, whereas sPLA 2 -V bound with a lower-affinity k d of 951 nmol/L ( Figure 5A ). To study the effect of binding to proteoglycans on the enzymatic activity, LDL was incubated with increasing concentrations of free or proteoglycans-bound sPLA 2 -IIA and sPLA 2 -V. These experiments indicated that LDL is a better substrate for sPLA 2 -V than for sPLA 2 -IIA, corroborating results shown in supplemental Figure VI . More important, the data in printed Figure 5B demonstrate that when sPLA 2 -V was bound to proteoglycans, the hydrolysis of LDL phospholipids increased significantly. This upregulation of enzymatic activity on LDL phospholipids by binding to proteoglycans was not observed for sPLA 2 -IIA under similar conditions ( Figure 4B ).
Induction of sPLA 2 -V and sPLA 2 -IIA Expression in Mouse Aorta
After 4 weeks on a Western diet (0.15% cholesterol, 21% cacao fat), sPLA 2 -V mRNA and protein were induced significantly in the aortas of C57BL/6 mice compared with animals on chow diet ( Figure 5A ). Furthermore, the apoEϫLDL receptor double-deficient mice, which develop hyperlipidemia and spontaneous atherosclerosis without a Western diet, showed elevated sPLA 2 -V protein expression in aorta similar to that of C57BL/6 on the Western diet ( Figure 5B ). There was no effect of the Western diet treatment on the spontaneous high levels of enzyme expression in the double knockout mice. On the other hand, acute inflammation triggered by an intraperitoneal injection with lipopolysaccharide (5 mg/kg) lipopolysaccharide did not change sPLA 2 -V expression in S-labeled proteoglycans (2.000 cpm, 0.030 g) purified from human arterial SMCs. Apparent affinity dissociation constants were determined by 1-site hyperbola binding curves fitted to the data. Added sPLA 2 -IIA and sPLA 2 -V are indicated in the x axis. B, LDL (20 g apoB, 1.38 mol/L of phospholipids) was added to free or proteoglycans-bound sPLA 2 -IIA and sPLA 2 -V samples (shown in Figure 4A ). After 2-hour incubation at 37°C, enzymatic activity was monitored by measuring the free fatty acids content. sPLA 2 C57BL/6 mice but induced significantly the expression of sPLA 2 -IIA in the aorta of the mice transgenic for this human enzyme. Treatment with the Western diet did not affect the aortic expression of sPLA 2 -IIA in the transgenic mice, but similar to the C57BL/6 mice, it increased the expression of sPLA 2 -V (data not shown).
Discussion
Expression of different phospholipase A 2 enzymes in arteries may represent redundant activities because of similar properties. However, our results indicate that group IIA and V sPLA 2 have dissimilar characteristics that could differentially modulate their postulated contribution to atherosclerosis. We found strong immunostaining of sPLA 2 -V extracellularly surrounding macrophage-like foam cells and in lipid-rich core areas. SPLA 2 -V was also present in SMCs in the media and neointima of intermediate and advanced lesions. However, only endothelial cells of advanced lesions showed positive immunostaining for sPLA 2 -V colocalizing with vWF. SPLA 2 -V was not detected in adventitia (Figure 1 ; supplemental Figure II ). This tissue distribution of sPLA 2 -V in atherosclerotic lesions differs in some aspects from that described previously for group IIA sPLA 2 by our laboratory and other laboratories. 4, 23, [25] [26] [27] [28] These apparent differences should be confirmed using common serial sections of the same tissue samples immunostained with antibodies specific against each enzyme. Levels of sPLA 2 -IIA and sPLA 2 -V mRNA in human lesions and in vitro human cell cultures indicate that cells present in lesions can produce the enzymes (supplemental Figure IV; Figure 3) . We have previously shown that SMCs are the main source of sPLA 2 -IIA in vivo in arteries and in cell cultures. 4, 29 The present data indicate that nonproliferating human coronary SMCs and aortic SMCs have a higher mRNA expression for sPLA 2 -IIA and sPLA 2 -V than those of uterine SMCs, aortic endothelial cells, M⌽, and lipid-loaded M⌽ (Figure 3 ). There are large differences in expression levels of the 2 enzymes in vascular cells and human lesions (Figure 3 ; supplemental Figure IV ) that could be caused by dissimilar transcription levels or differences in mRNA stability. Interestingly and in accord with the immunohistochemistry data, sPLA 2 -V mRNA but not sPLA 2 -IIA mRNA was detected in human endothelial cells and M⌽ and lipid-loaded M⌽ (Figure 3) . sPLA 2 -IIA mRNA was detected in CD14-positive M⌽ from human lesions; however, no Lipoproteins (500 g protein/mL) were incubated with 14 nmol/L (200 ng/mL) sPLA 2 -V for 24 hours at 37°C. Total lipids were extracted and analyzed by high-performance liquid chromatography as described in Materials and Methods. Values represent meanϮSD of 3 different experiments. PC indicates phosphatidylcholine; PE, phosphatidylethanolamine; NEFA, nonesterified free fatty acids; LL, lyso-phospholipids; Sp1, sphingomyelin 1; Sp2, sphingomyelin 2; ND, not detected. *PϽ0.05; **PϽ0.01; ***PϽ 0.001. mRNA could be detected in THP-1-derived M⌽ in vitro, even when loaded with lipids. This discrepancy between ex vivo and in vitro RT-PCR results suggests that sPLA 2 -IIA gene transcription may require both differentiation and local exposure of macrophages to specific stimuli. 30 In the C57BL/6 mouse, no group IIA enzyme is expressed. 21 However, we found sPLA 2 -V expression in the plaques of apoEϫLDL receptor double knockout of the same strain (Figure 2 ; supplemental Figure III) . The distribution pattern of sPLA 2 -V in mouse lesions was similar to that observed in human lesions. In addition, mouse showed shared areas positive for sPLA 2 -V and apoB. This could be caused by sPLA 2 -V entering the subendothelial space associated with apoB lipoproteins. However, we could not detect any association of the enzyme with lipoproteins after fractionation of serum in deuterium oxide gradients at physiological salt concentrations 31 (supplemental Figure IX) .
How sPLA 2 -IIA and sPLA 2 -V could modify circulating lipoproteins is not clear. We found that sPLA 2 -V but not sPLA 2 -IIA hydrolyzed lipoprotein phospholipids in the presence of complete serum. When purified plasma lipoproteins were used as substrates, the sPLA 2 -V preferentially hydrolyzed the phospholipidsin VLDL (K m ϭ546 mol/L), followed by those of HDL (K m ϭ1.3 mmol/L) and LDL (K m ϭ3 mmol/L; supplemental Figures VI and VII) . Differences in sphingomyelin content on the lipoproteins surface monolayer may be responsible in part for the dissimilar activities observed. 32 The group IIA sPLA 2 did not hydrolyze phospholipids of any of the native lipoproteins (supplemental Figure VI) . SPLA 2 -V has tryptophan residues in the interfacial binding region, which are absent in sPLA 2 -IIA. 33 This probably enables sPLA 2 -V but not type IIA to penetrate and hydrolyze phospholipid monolayers from and lipoproteins in extracellular fluid.
Treatment with sPLA 2 -V increased the association of LDL with arterial proteoglycans (supplemental Figure VIII) , thus suggesting that it is better suited than group II sPLA 2 for acting on lipoproteins in the extracellular arterial intima. We speculate that modification of apoB-containing lipoproteins by extracellular sPLA 2 -V may contribute to 2 atherogenic mechanisms: the increased entrapment of partially modified LDL and the generation of proinflammatory lipid products. 7, 34 This hypothesis is supported by recent data showing that sPLA 2 -V-modified LDL induces foam cell formation by a process that involves proteoglycans. 35 However, in spite of VLDL being a better substrate for the type V enzyme, we found no consistent increase of its binding to proteoglycans, probably because of the much lower affinity of proteoglycans for triglyceride-rich particles. 36 The consequences of HDL hydrolysis by sPLA 2 -V are unknown and deserve further investigation because a PC-deficient lipoprotein in the intima could be a poor acceptor of excess cell cholesterol. 37 Proteoglycans in the intima may not only contribute to the extracellular accumulation of the 2 enzymes but also to enhancing its activity. sPLA 2 -IIA associated to proteoglycans with higher affinity than sPLA 2 -V ( Figure 5A ). These differences are probably caused by the higher content of basic amino acids in sPLA 2 -IIA. However, the binding of sPLA 2 -V to proteoglycans resulted in a more significant increase in its capacity to hydrolyze LDL phospholipids than for sPLA 2 -IIA ( Figure 5B ). Mutational studies indicate that in human sPLA 2 -V, the interfacial-binding surface is separated from its glycosaminoglycan-binding surface, but in sPLA 2 -IIA, these areas partially overlap, and the glycosaminoglycan-binding surface is more diffuse. 33 Such differences suggest that in sPLA 2 -V, binding to proteoglycans may increase the exposure of the interfacial catalytic domain, thus facilitating the interaction with the substrate. In contrast, the binding of sPLA 2 -IIA to proteoglycans may block the interfacial domain and, as a consequence, impair association with the substrate.
Despite group IIA and V sPLA 2 enzymes being structurally similar, we found that a hyperlipidemic high-fat diet upregulates the expression in aorta of group V but not that of the group IIA. On the other hand, an acute inflammatory stimulus increased group IIA but not group V aortic expression ( Figure  5 ). The response of sPLA 2 -IIA to inflammatory stimuli is well known. 38, 39 However, we believe that our finding of the effect of dyslipidemia on the type V enzyme is novel. We speculate that this phenomenon may be related to the described lowlevel inflammation associated with hyperlipidemia. 40 In conclusion, our results showed clear differences between the 2 enzymes in the expression levels in vascular cells and in their ability to use human lipoproteins in serum as substrates. They also differ in the functional response to associations with arterial proteoglycans. Interestingly, in the mice models used, the enzymes differ in their response to high-fat diet and inflammatory challenge. The described properties profiles of these enzymes suggest that they can affect atherosclerosis by different pathways.
